Sanofi’s PERSEUS phase 3 study of tolebrutinib in primary progressive multiple sclerosis fails to meet primary endpoint: Paris Tuesday, December 16, 2025, 11:00 Hrs [IST] Sanofi ...

Cogent Biosciences (COGT) shares have surged after pivotal bezuclastinib data in imatinib-resistant aGIST. Read the latest ...

Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies December 15, 2025 2:00 ...

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosisPERSEUS phase 3 study in primary progressive multiple sclerosis ...

As fans celebrate the 250th anniversary of Jane Austen’s birth, scholars are still combing over documents to solve the mystery shrouding her final days.

As fans celebrate the 250th anniversary of Jane Austen’s birth, scholars are still combing over documents to solve the mystery shrouding her final days.

UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing*First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and ...

Schizophrenia has long been framed as a disorder of broken thoughts and fractured perception, but a new line of research ...

Cancer. That medical condition that anybody who is sick and goes to the hospital to see a doctor, will not want to hear the doctor pronounce that he or she has been diagnosed with it. Just hearing ...

UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing* First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK ...

When we think of heart disease, we tend to think of the big symptoms like chest pain, a heart attack or a stroke but our ...

We explore the disconnect between mycological cure and cosmetic recovery in Tinea Versicolor, focusing on managing patient ...